527
Participants
Start Date
November 13, 2019
Primary Completion Date
May 1, 2020
Study Completion Date
May 1, 2020
DEXYCU (dexamethasone intraocular suspension) 9%.
DEXYCU contains dexamethasone 9% w/w (103.4 mg/mL) as a sterile suspension for intraocular ophthalmic administration. DEXYCU is provided as a kit for administration of a single dose of 0.005 mL of 9% dexamethasone (equivalent to 517 micrograms of dexamethasone).
New York Eye Surgery Center, The Bronx
Island Eye Surgicenter, Westbury
SightMD, PLLC, Hauppauge
Wills Surgery Center, Jenkintown
Physicians Eyecare Center, Baltimore
Eye Physicians of Pinellas, PA, dba The Eye Institute of West Florida, Largo
The Eye Associates of Manatee, LLP, Bradenton
Eye Center South Locations, Dothan
VRF Eye Specialty Group, Memphis
Price Vision Group, Indianapolis
The Eye Centers of Racine and Kenosha, Racine
Jacksoneye, SC, Lake Villa
Hauser-Ross Eye Institute, Oak Brook
Tekwani Vision Center, St Louis
Discover Vision Centers, Independence
Silverstein Eye Centers, Kansas City
Valley Retina Institute, PA, McAllen
Inland Eye Specialists, Hemet
Harvard Eye Associates, Laguna Hills
Coastal Vision Medical Group, Orange
North Bay Eye Associates, Inc., Rohnert Park
Surgery Center of Central New Jersey, Pennington
Lead Sponsor
EyePoint Pharmaceuticals, Inc.
INDUSTRY